Zeillemaker A M, Veldkamp K E, van Kraaij M G, Hoekstra J B, Hoynck van Papendrecht A A, Diepersloot R J
Department of Surgery, Diakonessen Hospital, Utrecht, The Netherlands.
Foot Ankle Int. 1998 Mar;19(3):169-72. doi: 10.1177/107110079801900311.
In this study, 29 patients were hospitalized with a diabetic foot infection and were treated with piperacillin/tazobactam. Of these 23 patients who were evaluated for efficacy of treatment, 22 patients improved or were clinically cured. In seven patients (30%), there was persistence of one of the baseline pathogens. Adverse events were reported in 15 patients (58%), three of which were serious. Piperacillin/tazobactam may be useful as monotherapy in diabetic foot infection giving an adequate clinical response and the level of side effects equivalent to those of other broad-spectrum antibiotics.
